↓ Skip to main content

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

Overview of attention for article published in Clinical Cancer Research, October 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

blogs
1 blog
twitter
34 X users
patent
71 patents
weibo
6 weibo users

Citations

dimensions_citation
602 Dimensions

Readers on

mendeley
507 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Published in
Clinical Cancer Research, October 2013
DOI 10.1158/1078-0432.ccr-13-0458
Pubmed ID
Authors

Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark J. Smyth, Michael H. Kershaw, Phillip K. Darcy

Abstract

To determine the antitumor efficacy and toxicity of a novel combination approach involving adoptive T-cell immunotherapy using chimeric antigen receptor (CAR) T cells with an immunomodulatory reagent for blocking immunosuppression.

X Demographics

X Demographics

The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 507 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 6 1%
Germany 3 <1%
Korea, Republic of 1 <1%
France 1 <1%
Puerto Rico 1 <1%
Canada 1 <1%
Unknown 494 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 98 19%
Researcher 94 19%
Student > Bachelor 56 11%
Student > Master 49 10%
Student > Doctoral Student 27 5%
Other 78 15%
Unknown 105 21%
Readers by discipline Count As %
Medicine and Dentistry 94 19%
Agricultural and Biological Sciences 91 18%
Biochemistry, Genetics and Molecular Biology 79 16%
Immunology and Microbiology 63 12%
Pharmacology, Toxicology and Pharmaceutical Science 17 3%
Other 40 8%
Unknown 123 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 50. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#854,369
of 25,559,053 outputs
Outputs from Clinical Cancer Research
#555
of 13,257 outputs
Outputs of similar age
#7,510
of 224,526 outputs
Outputs of similar age from Clinical Cancer Research
#9
of 187 outputs
Altmetric has tracked 25,559,053 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,257 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,526 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 187 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.